Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523991 · ClinicalTrials.gov registry record · Phase 4
Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 457
- Enrollment target
NCT00523991 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 457 participants.
The verdict
NCT00523991, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 457 participants
- Enrollment target
Study Summary
A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18mcg of tiotropium inhalation capsules administered by Handihaler once daily plus Pro Re Nata (PRN) albuterol (salbutamol) vs. placebo plus PRN albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy.
Interventions
- DRUG Placebo
- DRUG tiotropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 457 participants |
| Start Date | 2007-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00523991
The ClinicalTrials.gov registry entry for NCT00523991 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00523991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00523991 about?
NCT00523991 is a clinical study titled "Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).". A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18mcg of tiotropium inhalation capsules administered by Handihaler once daily plus Pro Re Nata (PRN) albuterol (salbutamol) vs. placebo plus PRN albuterol (salbutamol) in chronic obstruc...
What is the current status of trial NCT00523991?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 457 participants. The study started on 2007-04.
What interventions are being tested in trial NCT00523991?
The interventions under investigation include: Placebo (DRUG), tiotropium (DRUG).
Who is sponsoring clinical trial NCT00523991?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.